Revelation Biosciences Announces Formation of Acute Kidney Injury Advisory Board James PhillipsApril 6, 2026
Revelation Biosciences Inc. Presents Additional Positive Data from Prime Clinical Study James PhillipsMarch 30, 2026
REMINDER: Revelation Biosciences to Host Fireside Chat at 38th Annual Roth Conference James PhillipsMarch 24, 2026
Revelation Biosciences to Host Fireside Chat at 38th Annual Roth Conference James PhillipsMarch 19, 2026
Revelation Biosciences, Inc. Announces Financial Results For the Three and Twelve Months Ended December 31, 2025 James PhillipsFebruary 26, 2026
Revelation Biosciences Inc. Announces 1-for-4 Reverse Stock Split Effective January 28, 2026 James PhillipsJanuary 26, 2026
Revelation Biosciences Inc. Announces Exercise of Warrants for $11 Million in Gross Proceeds James PhillipsJanuary 23, 2026
Revelation Biosciences Reaches Agreement with FDA on Gemini Approval Pathway for AKI James PhillipsJanuary 21, 2026
Revelation Biosciences Inc. to Present at The International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2026) James PhillipsJanuary 14, 2026
Revelation Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) James PhillipsJanuary 12, 2026
Revelation Biosciences Announces Initiation of GMP Manufacturing of GEMINI and Placebo to Support Later Stage Clinical Development James PhillipsJanuary 7, 2026
Revelation Biosciences Has Reached A Quorum For Its December 3, 2025 Special Meeting James PhillipsDecember 1, 2025
Revelation Biosciences On Track for End-of-Phase 1 Meeting With FDA Later This Year James PhillipsNovember 20, 2025
Revelation Biosciences, Inc. Announces Financial Results for the three and nine months ended September 30, 2025 James PhillipsNovember 6, 2025
Revelation Biosciences Inc. Announces Cancellation of Adjournment of October 29, 2025 Special Meeting of Stockholders and New Record Date James PhillipsOctober 29, 2025
Revelation Biosciences Inc. Announces Adjournment of October 15, 2025 Special Meeting of Stockholders to October 29, 2025 James PhillipsOctober 15, 2025
Revelation Biosciences Inc. Announces Exercise of Warrants for $9.6 Million in Gross Proceeds James PhillipsSeptember 11, 2025
Revelation Biosciences Announces Special Webcast to Review Positive Top-line Clinical Data James PhillipsSeptember 10, 2025
Reminder - Webcast/Conference Call to Discuss Fantastic PRIME Phase 1b Top-line Data James PhillipsSeptember 9, 2025
Revelation Biosciences Announces Groundbreaking Top-line Results from PRIME Clinical Study James PhillipsSeptember 9, 2025
